Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: China-Based Biotech Company Seeking Global In-Licensing Opportunities in Oncology Indications with Potential for China Market

11 Oct

A biotech company founded in 2016 with several offices in China is VC backed with $150M Series A funding followed by $260 MM Series B funding. With immuno-oncology as the firm’s core therapeutic focus, the company strives to lead Chinese research to the global market through its world class R&D team, its innovative portfolio, and an open innovation strategy. The company has a rich developing pipeline of oncology assets and is currently seeking in-licensing and partnership opportunities globally. The firm can invest in both private and public companies, depending on development stage of assets. The firm’s investment size depends on applicable deals.

The firm is particularly interested in first in class, truly innovative oncology assets from pre-clinical to market except for CAR-T therapy. The firm is currently focused on opportunities for the greater China market.

The firm’s team is flexible and is open to working with all different kinds of management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Eastern USA-Based VC Firm Invests Up to $15M in Early-Stage Companies Working on Cancer Therapeutics & Regenerative Medicine

11 Oct

A venture capital firm based in Eastern USA makes initial investments from $5-$15M with $35M over the lifetime of the company. The firm invests globally and has particular experience with partners located in the United States, Israel, and the United Kingdom.

The firm seeks early-stage nanotechnology and stem cell research, particularly in cancer, therapeutic and regenerative medicine. The firm is primarily interested in clinical stage Ph I/II technology. The firm focuses their expertise in regenerative and therapeutic medicine, with a focus on stem cell biology, immunology, oncology, and nanotechnology to identify opportunities in the treatment of a broad range of diseases. Specific to oncology, the firm is interested in novel cancer therapies, immunotherapy, new chemotherapies, targeted therapy, management of adverse consequences, and quality of life improvement.

The firm requires management teams with experience in the field. The firm seeks board representation post-investment and remains actively supportive with portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Private Cross-Border Investment Firm in USA and China Seeks to Invest in Disruptive Medical Device Companies, Assisting Them With China Market Entry

11 Oct

A private investment firm with offices in USA and China is focused on medical device technologies. The firm is formed by pharmaceutical and medical device industry veterans and high-net-worth individuals with a committed capital of US$40 million. Typical investment size ranges from US $500K – 5 million. The firm is open to leading or following in a financing round. Since 2016, the firm has begun broadening its geographic exposure and is currently seeking seed to early-stage opportunities from the US, Canada, Israel, and China.

The firm is interested in unique, disruptive medical device technologies with a focus on the following target markets: ophthalmic diagnostic or therapeutic device; visual optics technology; home use and personal care device; in-vitro diagnostics (IVD); and surgical equipment and consumables. The firm considers products that have at least completed prototype and obtained in-vivo proof-of-concept.

The firm is looking for competent management teams with strong sector expertise. The firm can request board representation after investment on a case-by-case basis. The firm does not focus only on products with a China angle, however, it can aid in identifying strategic partners in the Chinese market. The firm has expertise in helping portfolio companies in China Strategy, market strategy, regulatory strategy, and exit strategy.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: